A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.

Background: To determine the maximum tolerated dose (MTD), safety, potential pharmacokinetic (PK) interactions, and effect on liver histology of trabectedin in combination with pegylated liposomal doxorubicin (PLD) for advanced malignancies.

Patients And Methods: Entry criteria for the 36 patients included normal liver function, prior doxorubicin exposure <250 mg/m(2), and normal cardiac function. A 1-h PLD (30 mg/m(2)) infusion was followed immediately by one of six trabectedin doses (0.

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.

The objective of this study was to determine the objective response rate in patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer to treatment with trabectedin (Yondelis) administered as a 3-h infusion weekly for 3 weeks of a 4-week cycle. We carried out a multicentre Phase II trial of trabectedin in patients with advanced recurrent ovarian cancer. Trabectedin (0.

Incidence of respiratory cancer among workers exposed to chloromethyl-ethers.

A factory in France had used technical-grade chloromethyl-methyl-ether in the manufacture of anion exchange resins since 1958. Technical-grade chloromethyl-methyl-ether contains a human lung carcinogen, bis-chloromethyl-ether. The purpose of this cohort study was to determine if workers at the factory whose jobs had involved potential exposure to technical chloromethyl-methyl-ether had a higher incidence of lung cancer than coworkers, or others without potential exposure.